Solid Biosciences Inc. (SLDB): Price and Financial Metrics


Solid Biosciences Inc. (SLDB)

Today's Latest Price: $2.63 USD

0.13 (5.20%)

Updated Aug 7 12:00am

Add SLDB to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 344 in Biotech

See all "A" rated Strong Buy stocks

SLDB Daily Price Range
SLDB 52-Week Price Range

SLDB Stock Price Chart Technical Analysis Charts


SLDB Price/Volume Stats

Current price $2.63 52-week high $13.58
Prev. close $2.50 52-week low $1.96
Day low $2.47 Volume 155,600
Day high $2.67 Avg. volume 357,938
50-day MA $2.93 Dividend yield N/A
200-day MA $3.77 Market Cap 121.17M

Solid Biosciences Inc. (SLDB) Company Bio


Solid Biosciences, LLC engages in identifying and developing gene therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene transfer candidate that is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients’ muscles. The company was formerly known as Solid Ventures, LLC and changed its name to Solid Biosciences, LLC in June 2015. Solid Biosciences, LLC was founded in 2013 and is based in Cambridge, Massachusetts.





SLDB Latest News Stream


Event/Time News Detail
Loading, please wait...

SLDB Latest Social Stream


Loading social stream, please wait...

View Full SLDB Social Stream

Latest SLDB News From Around the Web

Below are the latest news stories about Solid Biosciences Inc that investors may wish to consider to help them evaluate SLDB as an investment opportunity.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Solid Biosciences Inc. (SLDB) Investigation

NEW YORK, NY / ACCESSWIRE / July 28, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Solid Biosciences Inc.

Yahoo | July 28, 2020

FDA maintains clinical hold on Solid Bio's Ignite DMD trial

The FDA notifies Solid Biosciences (SLDB) that its IGNITE DMD Phase I/II clinical trial remains on clinical hold. In November 2019, the Agency placed IGNITE DMD on clinical hold as the result of a serious adverse event related to the study drug. The study evaluated gene therapy candidate SGT-001 in Duchenne...

Seeking Alpha | July 27, 2020

Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical Hold

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, today announced that it received written communication from the U.S. Food and Drug Administration (FDA) that the Company’s IGNITE DMD Phase I/II clinical trial remains on clinical hold. In November 2019, the FDA placed IGNITE DMD on clinical hold as the result of a serious adverse event (SAE) that occurred in the sixth patient dosed in the trial; as previously reported the SAE has fully resolved. In April 2020, Solid provided the FDA with information and measures intended to improve patient safety and in May 2020, Solid received written communication from the FDA that the trial remained on hold. In ...

Yahoo | July 24, 2020

Solid Biosciences Inc. (SLDB): Hedge Fund Sentiment Unchanged

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 5, 2020

Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors

CAMBRIDGE, Mass., June 18, 2020 -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy,.

Yahoo | June 18, 2020

Read More 'SLDB' Stories Here

SLDB Price Returns

1-mo -10.54%
3-mo 0.77%
6-mo -14.61%
1-year -55.12%
3-year N/A
5-year N/A
YTD -40.90%
2019 -83.40%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7011 seconds.